Joaquin Duato, J&J CEO (Jacquelyn Martin/AP Images)

J&J’s mul­ti­ple myelo­ma ther­a­pies dri­ve on­col­o­gy busi­ness de­spite slow Carvyk­ti sales

John­son & John­son de­fend­ed slow­er-than-ex­pect­ed sales of Carvyk­ti in the first quar­ter, with ex­ecs say­ing they ex­pect sales of the cell ther­a­py to ac­cel­er­ate in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.